Svjetlana Mohrmann

2.1k total citations
63 papers, 1.1k citations indexed

About

Svjetlana Mohrmann is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Svjetlana Mohrmann has authored 63 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Cancer Research, 29 papers in Oncology and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Svjetlana Mohrmann's work include Breast Cancer Treatment Studies (27 papers), Breast Lesions and Carcinomas (13 papers) and Medical Imaging Techniques and Applications (12 papers). Svjetlana Mohrmann is often cited by papers focused on Breast Cancer Treatment Studies (27 papers), Breast Lesions and Carcinomas (13 papers) and Medical Imaging Techniques and Applications (12 papers). Svjetlana Mohrmann collaborates with scholars based in Germany, United States and Switzerland. Svjetlana Mohrmann's co-authors include Tanja Fehm, Oleg Gluz, Ulrike Nitz, Gerald Antoch, Evelyn Ting, F. Jänicke, A. E. Schindler, Stefanie Corradini, W. Kühn and Jan Haussmann and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Svjetlana Mohrmann

60 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Svjetlana Mohrmann Germany 16 588 441 236 222 202 63 1.1k
Dara S. Ross United States 18 725 1.2× 381 0.9× 388 1.6× 361 1.6× 272 1.3× 58 1.2k
Anna Cardillo Italy 17 734 1.2× 613 1.4× 173 0.7× 151 0.7× 252 1.2× 29 1.1k
Hyesil Seol South Korea 15 480 0.8× 307 0.7× 244 1.0× 207 0.9× 264 1.3× 34 853
Yoshiaki Rai Japan 21 827 1.4× 421 1.0× 310 1.3× 106 0.5× 193 1.0× 55 1.2k
Lucrezia Silvestro Italy 14 603 1.0× 256 0.6× 139 0.6× 151 0.7× 125 0.6× 29 835
Shinobu Masuda Japan 16 496 0.8× 412 0.9× 242 1.0× 146 0.7× 220 1.1× 88 933
Jeremy Force United States 19 616 1.0× 588 1.3× 273 1.2× 163 0.7× 653 3.2× 49 1.4k
Chikako Shimizu Japan 17 626 1.1× 484 1.1× 166 0.7× 118 0.5× 157 0.8× 53 975
Encarna Adrover Spain 14 864 1.5× 366 0.8× 177 0.8× 101 0.5× 297 1.5× 40 1.1k
Armando Orlandi Italy 17 519 0.9× 248 0.6× 248 1.1× 100 0.5× 192 1.0× 90 879

Countries citing papers authored by Svjetlana Mohrmann

Since Specialization
Citations

This map shows the geographic impact of Svjetlana Mohrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Svjetlana Mohrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Svjetlana Mohrmann more than expected).

Fields of papers citing papers by Svjetlana Mohrmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Svjetlana Mohrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Svjetlana Mohrmann. The network helps show where Svjetlana Mohrmann may publish in the future.

Co-authorship network of co-authors of Svjetlana Mohrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Svjetlana Mohrmann. A scholar is included among the top collaborators of Svjetlana Mohrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Svjetlana Mohrmann. Svjetlana Mohrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Morawitz, Janna, Nils Martin Bruckmann, Frederic Dietzel, et al.. (2023). Conventional Imaging, MRI and 18F-FDG PET/MRI for N and M Staging in Patients with Newly Diagnosed Breast Cancer. Cancers. 15(14). 3646–3646. 3 indexed citations
3.
Matuschek, Christiane, Danny Jazmati, Edwin Bölke, et al.. (2022). Post-Neoadjuvant Treatment Strategies in Breast Cancer. Cancers. 14(5). 1246–1246. 11 indexed citations
4.
Jazmati, Danny, Edwin Bölke, Bálint Tamaskovics, et al.. (2022). Early Outcome, Cosmetic Result and Tolerability of an IOERT-Boost Prior to Adjuvant Whole-Breast Irradiation. Cancers. 14(15). 3636–3636. 1 indexed citations
5.
Morawitz, Janna, Nils Martin Bruckmann, Frederic Dietzel, et al.. (2021). Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 49(3). 992–1001. 39 indexed citations
6.
Bruckmann, Nils Martin, Julian Kirchner, Janna Morawitz, et al.. (2021). Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results. PLoS ONE. 16(12). e0260804–e0260804. 16 indexed citations
7.
Haussmann, Jan, Carolin Nestle-Kraemling, Edwin Bölke, et al.. (2020). Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancer. Strahlentherapie und Onkologie. 196(4). 386–397. 10 indexed citations
8.
Bruckmann, Nils Martin, Lino M. Sawicki, Julian Kirchner, et al.. (2020). Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2816–2825. 19 indexed citations
9.
Krawczyk, Natalia, F Meier-Stiegen, Hans Neubauer, et al.. (2019). Determination of the androgen receptor status of circulating tumour cells in metastatic breast cancer patients. BMC Cancer. 19(1). 1101–1101. 5 indexed citations
10.
Gluz, Oleg, C Liedtke, Jens Huober, et al.. (2016). Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial. Annals of Oncology. 27(6). 1035–1040. 10 indexed citations
11.
12.
Schouten, Philip C., Oleg Gluz, Nadia Harbeck, et al.. (2014). BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.. Journal of Clinical Oncology. 32(15_suppl). 11018–11018. 1 indexed citations
13.
Obenauer, Silvia, Svjetlana Mohrmann, Petros Martirosian, et al.. (2012). Arterial spin labelling perfusion MRI of breast cancer using FAIR TrueFISP: Initial results. Clinical Radiology. 68(3). e123–e127. 7 indexed citations
14.
Gluz, Oleg, Peter J. Wild, Evelyn Ting, et al.. (2008). Nuclear karyopherin α2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity. International Journal of Cancer. 123(6). 1433–1438. 66 indexed citations
15.
Gluz, Oleg, Ulrike Nitz, Nadia Harbeck, et al.. (2008). Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Annals of Oncology. 19(5). 861–870. 84 indexed citations
16.
Ting, Evelyn, Oleg Gluz, Alexander Herr, et al.. (2007). Protein Expression Profiling in High-Risk Breast Cancer Patients Treated with High-Dose or Conventional Dose–Dense Chemotherapy. Clinical Cancer Research. 13(2). 488–497. 57 indexed citations
17.
Diallo, Raihanatou, Evelyn Ting, Oleg Gluz, et al.. (2006). C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.. PubMed. 90. 177–85. 7 indexed citations
18.
Kröger, Nicolaus, Oleg Gluz, Svjetlana Mohrmann, et al.. (2006). Randomized Trial of Single Compared With Tandem High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation in Patients With Chemotherapy-Sensitive Metastatic Breast Cancer. Journal of Clinical Oncology. 24(24). 3919–3926. 10 indexed citations
19.
Thiel, Falk C., et al.. (2005). Komplementäre und alternative Methoden (CAM) bei Frauen mit Genital- oder Mammakarzinom: multizentrische Studie zur Prävalenz und Motivation. Geburtshilfe und Frauenheilkunde. 65(2). 178–185. 4 indexed citations
20.
Reichardt, Peter, Gϋnter von Minckwitz, Peter Thuss‐Patience, et al.. (2003). Multicenter phase II study of oral capecitabine (Xeloda“) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Annals of Oncology. 14(8). 1227–1233. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dara S. Ross Breakdown of academic impact, for papers by Anna Cardillo Breakdown of academic impact, for papers by Hyesil Seol Breakdown of academic impact, for papers by Yoshiaki Rai Breakdown of academic impact, for papers by Lucrezia Silvestro Breakdown of academic impact, for papers by Shinobu Masuda Breakdown of academic impact, for papers by Jeremy Force Breakdown of academic impact, for papers by Chikako Shimizu Breakdown of academic impact, for papers by Encarna Adrover Breakdown of academic impact, for papers by Armando Orlandi
Rankless by CCL
2026